Citrus Therapeutics co-Founder Presents CTZ1™ Groundbreaking Therapy for Age-Related Macular Degeneration (AMD) at Ophthalmology Innovation Summit XII
Presentation (linked below) highlights this novel vascular disruptive antioxidant agent for treating wet and dry AMD with potential synergy given concurrent therapies
Citrus Therapeutics to Present CTZ1™ Groundbreaking Therapy for Age-Related Macular Degeneration (AMD) at Ophthalmology Innovation Summit XII